{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:09:13Z","timestamp":1794852553205,"version":"4.9.1"},"reference-count":115,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T00:00:00Z","timestamp":1292284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neuroscience &amp; Therapeutics"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Even though noradrenaline has been recognized as one of the key neurotransmitters in the pathophysiology of major depression (MD), noradrenergic compounds have been less extensively utilized in clinical practice, compared to selective serotonin reuptake inhibitors (SSRIs). The development of the first selective noradrenergic reuptake inhibitor (NRI), Reboxetine, has not substantially changed the state of the art. In addition, Atomoxetine, a relatively pure NRI used for the treatment of ADHD, has shown mixed results when administered in augmentation to depressed subjects. Through a Medline search from 2000 to 2010, the present article provides an updated overview of the main pharmacological and clinical aspects of antidepressant classes that, partially or selectively, act on the noradrenergic systems. The noradrenergic action plays an important clinical effect in different antidepressant classes, as confirmed by the efficacy of dual action antidepressants such as the serotonin noradrenaline reuptake inhibitors (SNRIs), the noradrenergic and dopaminergic reuptake inhibitor (NDRI) Bupropion, and other compounds (e.g., Mianserin, Mirtazapine), which enhance the noradrenergic transmission. In addition, many tricyclics, such as Desipramine and Nortriptyline, have prevalent noradrenergic effect. Monoamine oxidase inhibitors (MAOIs), moreover, block the breakdown of serotonin, noradrenaline, dopamine and increase the availability of these monoamines. A novel class of antidepressants\u2014the triple reuptake inhibitors\u2014is under development to selectively act on serotonin, noradrenaline, and dopamine. Finally, the antidepressant effect of the atypical antipsychotic Quetiapine, indicated for the treatment of bipolar depression, is likely to be related to the noradrenergic action of its metabolite Norquetiapine. Even though a pure noradrenergic action might not be sufficient to obtain a full antidepressant effect, a pronoradrenergic action represents an important element for increasing the efficacy of mixed action antidepressants. In particular, the noradrenergic action seemed to be related to the motor activity, attention, and arousal.<\/jats:p>","DOI":"10.1111\/j.1755-5949.2010.00217.x","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T08:26:25Z","timestamp":1292315185000},"page":"723-732","source":"Crossref","is-referenced-by-count":77,"title":["The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects"],"prefix":"10.1111","volume":"17","author":[{"given":"Bernardo","family":"Dell\u2019Osso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carlotta","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Carlo","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,14]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1965.01730060001001"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.122.5.509"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.10.039"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00146.x"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2009.01529.x"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.09.025"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.7.1017"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.11.015"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2009.12.016"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1103"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.11"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/15622971003611319"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.08.011"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90344-2"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1994.16"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(95)00004-Z"},{"key":"e_1_2_14_18_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145704004080","article-title":"Antidepressants and brain monoaminergic systems: A dimensional approach to understanding their behavioural effects in depression and anxiety disorders","volume":"7","author":"Morilak DA","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199905001-00002"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.22283"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.11.022"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.159"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90203-8"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001032"},{"issue":"4","key":"e_1_2_14_25_2","first-page":"5","article-title":"Basic psychopharmacology of antidepressants, Part 1: Antidepressants have seven distinct mechanisms of action","volume":"59","author":"Stahl SM","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"e_1_2_14_26_2","first-page":"25","article-title":"Norepinephrine involvement in antidepressant action","volume":"61","author":"Frazer A","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_14_27_2","article-title":"Noradrenergic function in generalized anxiety disorder: Impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge","author":"Hood SD","year":"2010","journal-title":"J Psychopharmacol"},{"key":"e_1_2_14_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2005.03.009"},{"key":"e_1_2_14_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200307000-00001"},{"key":"e_1_2_14_30_2","first-page":"312","article-title":"Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat","volume":"283","author":"Boudet C","year":"1986","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_14_31_2","doi-asserted-by":"publisher","DOI":"10.1039\/b903035m"},{"key":"e_1_2_14_32_2","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-200033482"},{"key":"e_1_2_14_33_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.057554"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.17.2323"},{"key":"e_1_2_14_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300341"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150612"},{"key":"e_1_2_14_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199512020-00007"},{"key":"e_1_2_14_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200305000-00009"},{"key":"e_1_2_14_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150621"},{"key":"e_1_2_14_40_2","doi-asserted-by":"publisher","DOI":"10.1024\/0040-5930.66.5.335"},{"key":"e_1_2_14_41_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0893-133X(94)00058-8","article-title":"MAOIs in the contemporary treatment of depression","volume":"12","author":"Thase ME","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_14_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519050-00002"},{"key":"e_1_2_14_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00258.x"},{"key":"e_1_2_14_44_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1999.35.9.553217"},{"key":"e_1_2_14_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039060-00003"},{"key":"e_1_2_14_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60046-5"},{"key":"e_1_2_14_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318183796d"},{"key":"e_1_2_14_48_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.5.379"},{"key":"e_1_2_14_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2008.11.004"},{"issue":"1","key":"e_1_2_14_50_2","first-page":"26","article-title":"New approaches to the treatment of refractory depression","volume":"61","author":"Fava M","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_14_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102641"},{"key":"e_1_2_14_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9"},{"key":"e_1_2_14_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.059386"},{"key":"e_1_2_14_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2005.08.002"},{"key":"e_1_2_14_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00707.x"},{"key":"e_1_2_14_56_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544060-00002"},{"key":"e_1_2_14_57_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0066"},{"key":"e_1_2_14_58_2","first-page":"288","article-title":"Psychopharmacology for the clinician. Treating depression with selective norepinephrine reuptake inhibitors","volume":"31","author":"Blier F","year":"2006","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_14_59_2","doi-asserted-by":"publisher","DOI":"10.2165\/11314350-000000000-00000"},{"key":"e_1_2_14_60_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.58301"},{"key":"e_1_2_14_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1074"},{"key":"e_1_2_14_62_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.3.371"},{"key":"e_1_2_14_63_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115080-00007"},{"key":"e_1_2_14_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.012"},{"key":"e_1_2_14_65_2","first-page":"17","article-title":"Desvenlafaxine: Another \u201cme too\u201d drug?","volume":"25","author":"Sopko MA","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"e_1_2_14_66_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.01.2106"},{"key":"e_1_2_14_67_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.12.1787"},{"key":"e_1_2_14_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.006"},{"key":"e_1_2_14_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.08.010"},{"key":"e_1_2_14_70_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.6.987"},{"key":"e_1_2_14_71_2","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"key":"e_1_2_14_72_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730050-00007"},{"key":"e_1_2_14_73_2","doi-asserted-by":"publisher","DOI":"10.2165\/11310990-000000000-00000"},{"key":"e_1_2_14_74_2","first-page":"387","article-title":"Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan","volume":"51","author":"Chang TT","year":"2008","journal-title":"Chin J Physiol"},{"key":"e_1_2_14_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109348178"},{"key":"e_1_2_14_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00295-9"},{"key":"e_1_2_14_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90723-4"},{"key":"e_1_2_14_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61375-5"},{"key":"e_1_2_14_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(98)00044-X"},{"key":"e_1_2_14_80_2","first-page":"395","article-title":"Bupropion: A review of its mechanism of antidepressant activity","volume":"56","author":"Ascher JA","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_14_81_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(24)37928-5","article-title":"Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine","volume":"288","author":"Fryer JD","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_14_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2006.00178.x"},{"key":"e_1_2_14_83_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109106953"},{"key":"e_1_2_14_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.03.011"},{"key":"e_1_2_14_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109351966"},{"issue":"12","key":"e_1_2_14_86_2","first-page":"16","article-title":"Novel treatments for attention\u2010deficit\/hyperactivity disorder in children","volume":"63","author":"Spencer TJ","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_14_87_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v07n0305"},{"key":"e_1_2_14_88_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0803"},{"key":"e_1_2_14_89_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0507"},{"key":"e_1_2_14_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000239790.83707.ab"},{"key":"e_1_2_14_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.06.027"},{"key":"e_1_2_14_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.07.004"},{"key":"e_1_2_14_93_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0215"},{"key":"e_1_2_14_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.05.042"},{"key":"e_1_2_14_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb04989.x"},{"key":"e_1_2_14_96_2","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1007\/BF00172628","article-title":"Trazodone in late life depressive states: A double\u2010blind multicenter study versus amitriptyline and mianserin","volume":"95","author":"Altamura AC","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"e_1_2_14_97_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.59.690.229"},{"key":"e_1_2_14_98_2","first-page":"497","article-title":"Mianserin: Pharmacology and clinical aspects of an effective antidepressive agents","volume":"111","author":"Demling J","year":"1993","journal-title":"Fortschr Med"},{"key":"e_1_2_14_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11381-3"},{"key":"e_1_2_14_100_2","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150599"},{"key":"e_1_2_14_101_2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.20452\/pamw.743","article-title":"First\u2010line pharmacotherapies for depression: What is the best choice?","volume":"119","author":"Koenig AM","year":"2009","journal-title":"Pol Arch Med Wewn"},{"key":"e_1_2_14_102_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923050-00006"},{"key":"e_1_2_14_103_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.143610"},{"key":"e_1_2_14_104_2","doi-asserted-by":"publisher","DOI":"10.2174\/157015908787386078"},{"key":"e_1_2_14_105_2","doi-asserted-by":"publisher","DOI":"10.1136\/ebmh1086"},{"key":"e_1_2_14_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.10.007"},{"key":"e_1_2_14_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.03.023"},{"key":"e_1_2_14_108_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0084"},{"key":"e_1_2_14_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-008-0849-0"},{"key":"e_1_2_14_110_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988119400800407"},{"key":"e_1_2_14_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)00057-3"},{"key":"e_1_2_14_112_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1211"},{"key":"e_1_2_14_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.08.010"},{"key":"e_1_2_14_114_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107083808"},{"key":"e_1_2_14_115_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020320"},{"key":"e_1_2_14_116_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802622726"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2010.00217.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5949.2010.00217.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:57:26Z","timestamp":1740769046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2010.00217.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,14]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1111\/j.1755-5949.2010.00217.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00217.x","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,14]]}}}